{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:18:59Z","timestamp":1787678339155,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110123","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:50:19Z","timestamp":1781711419000},"page":"110123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rational design and structural insights of osthole-derived selective AKR1C3 inhibitors with cellular activity"],"prefix":"10.1016","volume":"180","author":[{"given":"Xuehua","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoci","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianye","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingna","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110123_bb0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/bj3510067","article-title":"Human 3\u03b1-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones","volume":"351","author":"Penning","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2026.110123_bb0010","article-title":"AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies","volume":"15","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110123_bb0015","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/CM9.0000000000001379","article-title":"Roles of AKR1C3 in malignancy","volume":"134","author":"Xiao","year":"2021","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.bioorg.2026.110123_bb0020","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","article-title":"AKR1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase): roles in malignancy and endocrine disorders","volume":"489","author":"Penning","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.bioorg.2026.110123_bb0025","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/acs.jmedchem.9b02138","article-title":"Overview of AKR1C3: inhibitor achievements and disease insights","volume":"63","author":"Liu","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110123_bb0030","first-page":"9","article-title":"Dysregulated androgen synthesis and anti-androgen resistance in advanced prostate cancer","volume":"9","author":"Gao","year":"2021","journal-title":"Am. J. Clin. Exp. Urol."},{"key":"10.1016\/j.bioorg.2026.110123_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1535-7163.MCT-16-0186","article-title":"Inhibition of AKR1C3 activation overcomes resistance to Abiraterone in advanced prostate cancer","volume":"16","author":"Liu","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110123_bb0040","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-18-1322","article-title":"AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-targeted therapies in advanced prostate cancer","volume":"18","author":"Liu","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110123_bb0045","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1535-7163.MCT-20-0015","article-title":"Cross-resistance among next-generation antiandrogen drugs through the AKR1C3\/AR-V7 axis in advanced prostate cancer","volume":"19","author":"Zhao","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110123_bb0050","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41388-022-02566-6","article-title":"Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer","volume":"42","author":"Yang","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2026.110123_bb0055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jsbmb.2013.05.012","article-title":"AKR1C3 as a target in castrate resistant prostate cancer","volume":"137","author":"Adeniji","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110123_bb0060","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1080\/17425255.2017.1376648","article-title":"Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes","volume":"13","author":"Alshogran","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bioorg.2026.110123_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110654","article-title":"Inhibition of AKR1Cs by liquiritigenin and the structural basis","volume":"385","author":"Liu","year":"2023","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.bioorg.2026.110123_bb0070","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1080\/13543776.2017.1379503","article-title":"Aldo-keto reductase (AKR) 1C3 inhibitors: a patent review","volume":"27","author":"Penning","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2026.110123_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115013","article-title":"Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer","volume":"247","author":"Liu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110123_bb0080","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1021\/acs.jmedchem.5c00050","article-title":"Discovery and optimization of a covalent AKR1C3 inhibitor","volume":"68","author":"Grams","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110123_bb0085","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1021\/acs.jmedchem.4c03035","article-title":"Discovery of highly potent AKR1C3 inhibitors treating Sorafenib-resistant hepatocellular carcinoma","volume":"68","author":"Xing","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110123_bb0090","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1021\/acs.jmedchem.3c00213","article-title":"Development of biaryl-containing aldo-keto reductase 1C3 (AKR1C3) inhibitors for reversing AKR1C3-mediated drug resistance in cancer treatment","volume":"66","author":"He","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110123_bb0095","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10637-014-0130-5","article-title":"In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17\u03b2-hydroxysteroid dehydrogenase type 5 (17\u03b2HSD5; AKR1C3)","volume":"32","author":"Kikuchi","year":"2014","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bioorg.2026.110123_bb0100","series-title":"A novel AKR1C3 inhibitor demonstrates strong efficacy in a marmoset monkey endometriosis model., in 63rd Annual Scientific Meeting of the Society-for-Reproductive-Investigation","author":"Peters","year":"2016"},{"key":"10.1016\/j.bioorg.2026.110123_bb0105","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10637-014-0101-x","article-title":"Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-Centre phase I\/II study","volume":"32","author":"Loriot","year":"2014","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bioorg.2026.110123_bb0110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40268-023-00427-5","article-title":"Hepatotoxicity of AKR1C3 inhibitor BAY1128688: findings from an early terminated phase IIa trial for the treatment of endometriosis","volume":"23","author":"Hilpert","year":"2023","journal-title":"Drugs. R. D."},{"key":"10.1016\/j.bioorg.2026.110123_bb0115","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/cpt.3010","article-title":"Quantitative systems toxicology identifies independent mechanisms for hepatotoxicity and bilirubin elevations due to AKR1C3 inhibitor BAY1128688","volume":"114","author":"Battista","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.110123_bb0120","doi-asserted-by":"crossref","unstructured":"H. Firoz, R. Ali, F.A. Khan, P. Kakkar, R.K. Soni, M.A. Assiri, S. Ahamad, M. SaquibM.K. Hussain, Coumarins as versatile scaffolds: innovative synthetic strategies for generating diverse heterocyclic libraries in drug discovery, J. Mol. Struct. 1352 (2026). DOI: https:\/\/doi.org\/10.1016\/j.molstruc.2025.144426.","DOI":"10.1016\/j.molstruc.2025.144426"},{"key":"10.1016\/j.bioorg.2026.110123_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117088","article-title":"Exploring the anticancer potential and mechanisms of action of natural coumarins and isocoumarins","volume":"282","author":"Aqib","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110123_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155972","article-title":"Coumarins as versatile therapeutic phytomolecules: a systematic review","volume":"134","author":"Hussain","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2026.110123_bb0135","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1021\/acs.jmedchem.0c00939","article-title":"Development of novel AKR1C3 inhibitors as new potential treatment for castration-resistant prostate cancer","volume":"63","author":"Endo","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110123_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400081","article-title":"Coumarin-based aldo-keto reductase family 1C (AKR1C) 2 and 3 inhibitors","volume":"19","author":"Jonnalagadda","year":"2024","journal-title":"Chem. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110123_bb0145","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1021\/acsmedchemlett.4c00150","article-title":"AI based discovery of a new AKR1C3 inhibitor for anticancer applications","volume":"15","author":"Pippione","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.110123_bb0150","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00044-021-02775-w","article-title":"Osthole: an overview of its sources, biological activities, and modification development","volume":"30","author":"Sun","year":"2021","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.110123_bb0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s43440-024-00685-3","article-title":"Anticancer potential of osthole: targeting gynecological tumors and breast cancer","volume":"77","author":"Han","year":"2024","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bioorg.2026.110123_bb0160","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1142\/S0192415X24500678","article-title":"Osthole, a coumarin from Cnidium monnieri: a review on its pharmacology, pharmacokinetics, safety, and innovative drug delivery platforms","volume":"52","author":"Lin","year":"2024","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.bioorg.2026.110123_bb0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsbmb.2010.11.004","article-title":"Inhibitors of type 5 17\u03b2-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights","volume":"125","author":"Byrns","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110123_bb0170","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202000519","article-title":"Design, synthesis and cytotoxicity evaluation of novel indole derivatives containing benzoic acid group as potential AKR1C3 inhibitors","volume":"17","author":"Sun","year":"2020","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.bioorg.2026.110123_bb0175","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1002\/ps.6056","article-title":"Construction of oxime ester derivatives of osthole from Cnidium monnieri, and evaluation of their agricultural activities and control efficiency","volume":"76","author":"Ren","year":"2020","journal-title":"Pest Manag. Sci."},{"key":"10.1016\/j.bioorg.2026.110123_bb0180","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.febslet.2011.11.023","article-title":"The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase","volume":"586","author":"Zheng","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bioorg.2026.110123_bb0185","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.1016\/j.bmc.2018.10.044","article-title":"Screening, synthesis, crystal structure, and molecular basis of 6-amino-4-phenyl-1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles as novel AKR1C3 inhibitors","volume":"26","author":"Zheng","year":"2018","journal-title":"Bioorg. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826006590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826006590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:28:26Z","timestamp":1787675306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826006590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"alternative-id":["S0045206826006590"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110123","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rational design and structural insights of osthole-derived selective AKR1C3 inhibitors with cellular activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110123"}}